…. which would bring it to market earlier. Great news if it works, lets wait and see the SVR figures before we get too excited though.
Wall Street analysts still have high hopes for VX-950, a developmental-stage treatment for hepatitis C. Sales of VX-950 are expected to peak at $1.4 billion in 2011, according to McDonald.
The […]

The Vertex VX-950 does look impressive even at this early stage of clinical trials. I wouldn’t hold your breath but it looks worthy of keeping an eye on.
Data announced today by Vertex show that VX-950, an investigational hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a , achieved a […]